Platinum Investment Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Platinum Investment Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-175,339	Closed	-$112K	–	105
2019 Q1	$112K	Hold	175,339	–	–	﹤0.01%	98
2018 Q4	$306K	Hold	175,339	–	–	0.01%	87
2018 Q3	$1.01M	Hold	175,339	–	–	0.03%	74
2018 Q2	$1.05M	Hold	175,339	–	–	0.02%	72
2018 Q1	$1.25M	Buy	+175,339	New	+$1.33M	0.04%	64

Other funds holding TRIL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Platinum Investment Management's TRIL Position: Q2 2019 in Review

Platinum Investment Management sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2019, closing a stake of 175,339 shares — an estimated $112K sold.

Platinum Investment Management first reported a position in TRIL in Q1 2018 and held it in 5 quarters. The position peaked at $1.25M in Q1 2018. 19 funds tracked by Wall St. Rank hold TRIL as of Q2 2019.

Platinum Investment Management reported no remaining Trillium Therapeutics Inc. position as of Q2 2019 after selling out during the quarter.
Platinum Investment Management sold 175,339 Trillium Therapeutics Inc. shares in Q2 2019, an estimated $112K.
Platinum Investment Management first reported a position in Trillium Therapeutics Inc. in Q1 2018 and held it in 5 quarters.
Platinum Investment Management's Trillium Therapeutics Inc. position peaked at $1.25M in Q1 2018.
19 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2019.

Based on Platinum Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.